61 research outputs found
Vegetable waste as substrate and source of suitable microflora for bio-hydrogen production
No full textSelf-fermentation of cellulosic substrates to produce biohydrogen without inoculum addition nor pretreatments was investigated. Dark fermentation of two different substrates made of leaf-shaped vegetable refuses (V) and leaf-shaped vegetable refuses plus potato peels (VP), was taken in consideration. Batch experiments were carried out, under two mesophilic anaerobic conditions (28 and 37°C), in order to isolate and to identify potential H2-producing bacterial strains contained in the vegetable extracts. The effect of initial glucose concentration (at 1, 5 and 10g/L) on fermentative H2 production by the isolates was also evaluated.H2 production from self-fermentation of both biomasses was found to be feasible, without methane evolution, showing the highest yield for V biomass at 28°C (24L/kgVS). The pH control of the culture medium proved to be a critical parameter. The isolates had sequence similarities ≥98% with already known strains, belonging to the family Enterobacteriaceae (γ-proteobacteria) and Streptococcaceae (Firmicutes). Four genera found in the samples, namely Pectobacterium, Raoultella, Rahnella and Lactococcus have not been previously described for H2 production from glucose. The isolates showed higher yield (1.6-2.2molH2/molglucoseadded) at low glucose concentration (1g/L), while the maximum H2 production ranged from 410 to 1016mL/L and was obtained at a substrate concentration of 10g/L. The results suggested that vegetable waste can be effectively used as both, substrate and source of suitable microflora for bio-hydrogen production. © 2014 Elsevier Ltd
Age-related prevalence of platelet-associated Immunoglobulins G in nonthrombocytopenic patients with autoimmune thyroid disease and autoimmune polyglandular syndrome
No full textA rapid, simple, and inexpensive step facilitates RNA extraction from whole blood cells
No full text[No abstract available
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO)
No full textPhase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
No full textSafety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience
No full textPurpose The everolimus and exemestane combination represents a treatment option for the endocrine sensitive metastatic breast cancer (MBC) patients. The toxicity profile reported in the Bolero 2 trial showed the feasibility in the selected patients. Few data are available for the unselected population. Methods In order to evaluate the safety in the unselected population of the clinical practice and to evaluate a possible association of toxicities with previous treatments, clinical data from 181 consecutive patients were retrospectively collected. Results Due to toxic events, everolimus dosage was reduced to 5 mg in 27% of patients. No association was found in the analysis between toxicity and number of prior therapies, neither between toxicity and response. In the multivariate analysis the previous exposure to anthracyclines for advanced disease represents the only predictive factor of developing grade ≥2 toxicity (OR = 2.85 CI 95% 1.07–7.59, p = 0.036). Conclusions The association of everolimus and exemestane has confirmed to be a safe and effective treatment for endocrine sensitive MBC patients even in routine clinical practice. The rate of treatment discontinuation due to toxicity is low and none association between previous number of treatments and response or between toxicity and response was found
L'ecografia endoluminale per la diagnosi precoce delle recidive locali per carcinoma del retto
No full textInduction therapy before surgery for non-small cell lung cancer
No full textSurgery alone is currently still accepted as the principal therapy for cure for patients with localized non-small cell lung cancer. The optimal therapy in locally advanced and unresectable stage III disease remains unclear. The limited performance of each single therapeutic strategy (surgery, radiotherapy, or chemotherapy) in the treatment of locally advanced non-small cell lung cancer accounted for the rationale of the many attempts at improvement by integrating the different approaches. In recent years, to improve clinical outcome, chemotherapy or chemoradiation followed by surgery, and definitive chemoradiation have commonly been used. Despite numerous phase-II trials, little evidence from randomized phase-III trials has been generated. The ongoing randomized trials will probably provide more reliable indications to define the management of the large number of patients with locally advanced disease
Increased expression of thyroid hormone receptor isoforms in end-stage human congestive heart failure.
No full text- …
